These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17538174)

  • 1. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
    Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
    J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
    Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
    Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
    Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
    Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma.
    Sung CO; Choi CH; Ko YH; Ju H; Choi YL; Kim N; Kang SY; Ha SY; Choi K; Bae DS; Lee JW; Kim TJ; Song SY; Kim BG
    Cancer Genet; 2013 May; 206(5):145-53. PubMed ID: 23726144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic fibroblast growth factor and receptor expression in human ovarian cancer.
    Crickard K; Gross JL; Crickard U; Yoonessi M; Lele S; Herblin WF; Eidsvoog K
    Gynecol Oncol; 1994 Nov; 55(2):277-84. PubMed ID: 7959296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
    Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.
    Tominaga E; Tsuda H; Arao T; Nishimura S; Takano M; Kataoka F; Nomura H; Hirasawa A; Aoki D; Nishio K
    Gynecol Oncol; 2010 Aug; 118(2):160-6. PubMed ID: 20537689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.
    Sunde JS; Donninger H; Wu K; Johnson ME; Pestell RG; Rose GS; Mok SC; Brady J; Bonome T; Birrer MJ
    Cancer Res; 2006 Sep; 66(17):8404-12. PubMed ID: 16951150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
    van Dekken H; Tilanus HW; Hop WC; Dinjens WN; Wink JC; Vissers KJ; van Marion R
    Cancer Genet Cytogenet; 2009 Feb; 189(1):37-42. PubMed ID: 19167610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot-specific expression of fibroblast growth factors in human adipose tissue.
    Gabrielsson BG; Johansson JM; Jennische E; Jernås M; Itoh Y; Peltonen M; Olbers T; Lönn L; Lönroth H; Sjöström L; Carlsson B; Carlsson LM; Lönn M
    Obes Res; 2002 Jul; 10(7):608-16. PubMed ID: 12105282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
    Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
    Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of degenerate oligonucleotide-primed polymerase chain reaction amplification and labeling methods on the sensitivity and specificity of metaphase- and array-based comparative genomic hybridization.
    Tsubosa Y; Sugihara H; Mukaisho K; Kamitani S; Peng DF; Ling ZQ; Tani T; Hattori T
    Cancer Genet Cytogenet; 2005 Apr; 158(2):156-66. PubMed ID: 15796963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.
    Kloth JN; Oosting J; van Wezel T; Szuhai K; Knijnenburg J; Gorter A; Kenter GG; Fleuren GJ; Jordanova ES
    BMC Genomics; 2007 Feb; 8():53. PubMed ID: 17311676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
    Miller CT; Aggarwal S; Lin TK; Dagenais SL; Contreras JI; Orringer MB; Glover TW; Beer DG; Lin L
    Cancer Res; 2003 Jul; 63(14):4136-43. PubMed ID: 12874018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
    Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
    Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.